Management options for cast nephropathy in multiple myeloma

Area of Science:

• Nephrology
• Hematology
• Oncology

Background:

• Multiple myeloma can cause cast nephropathy, a serious kidney complication.
• Accurate and timely diagnosis is essential for effective management.

Purpose of the Study:

• To review the role of immunoglobulin free light chain (FLC) immunoassays in diagnosing cast nephropathy.
• To evaluate novel chemotherapy agents and high cut-off hemodialysis for managing cast nephropathy in multiple myeloma.

Main Methods:

• Review of current literature on FLC immunoassays.
• Analysis of pilot studies on novel chemotherapy and high cut-off hemodialysis.
• Discussion of prognostic factors in cast nephropathy.

Main Results:

• Serum FLC measurement offers sensitive and specific screening for cast nephropathy.
• A rapid decline in FLC levels within 3 weeks predicts renal recovery, enhanced by novel chemotherapy.
• High cut-off hemodialysis demonstrates efficacy in removing FLC, though plasma exchange does not offer clinical benefit.

Conclusions:

• Prompt diagnosis and chemotherapy initiation are critical for renal recovery in cast nephropathy.
• Patients with severe acute kidney injury and dialysis dependence have a poor prognosis.
• A randomized controlled trial of high cut-off hemodialysis with bortezomib-based chemotherapy is ongoing.